

AQEMIA

http://www.aqemia.com/

#DRUGDISCOVERY
#MACHINELEARNING
#BIOTECH

VALUE FOR CLIENT

Our aim is to generate innovative «in silico» molecules that have better chances to translate in «in vitro/vivo» hit and leads, and accelerate discovery phase.

VALUE FOR USER

Discovering more innovative molecules, possibly on difficult targets, will eventually lead to new / better treatments for patients.

BUSINESS CASE

We develop collaborations with pharmas & biotechs to generate hit/leads on their targets. We also build our own discovery pipeline on selected targets.

INSIGHTS

Aqemia unique structure-based algorithms predict drug-target affinity both fast (10 000x faster vs. competition) and precisely, without dataset to train on.

GENERATION OF INNOVATIVE MOLECULES FOR DRUG DISCOVERY - WITHOUT TRAINING DATA

Finding new drugs with AI is difficult as you need data to train on, which aren't usually available especially for drug-target affinity - first criteria for a future drug.
Typical use case for AI in drug discovery is thus constrained to proposing lead molecules around a given scaffhold with known activity.

Since Aqemia technology combines AI with structure based affinity prediction which does not need training data, it is possible to explore new chemical spaces and address more innovative use cases. Aqemia use cases include typical lead optimization but also identification of early hits for new targets and generation of back up series with new chemical spaces.

DATE OF CREATION

June 2019

GEOGRAPHIC COVERAGE

Objective to be global

HQ LOCALIZATION

Paris, France

FOUNDERS

Maximilien Levesque
(CEO & Co-Founder)
Emmanuelle Martiano
(COO & Co-Founder)

FUNDINGS

1.6M€

INVESTORS

Elaia Partners
Bpifrance
Business Angels
PSL (Paris, Sciences & Lettres)